Our Firm is representing a number of Lipitor lawsuit plaintiffs, and we are looking forward to the commencement of this first trial. As a bellwether trial, it may provide important clues as to how juries will rule in similar Lipitor diabetes claims.
New York, New York (PRWEB) February 09, 2015
Lipitor lawsuits (http://www.lipitorlawsuitcenter.com/) alleging that use of the cholesterol-lowering statin caused patients to develop Type 2 diabetes continue to move forward in U.S. District Court, District of South Carolina, Bernstein Liebhard LLP reports. According to an Order issued on February 4th, the Court has adopted new deadlines for certain matters pertaining to the proceeding’s first bellwether trial. Jury selection for that trial is now tentatively scheduled to begin on October 19, 2015. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502)
“Our Firm is representing a number of Lipitor lawsuit plaintiffs, and we are looking forward to the commencement of this first trial. As a bellwether trial, it may provide important clues as to how juries will rule in similar Lipitor diabetes claims,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free and confidential case reviews to individuals who may have been harmed by Lipitor.
Lipitor Diabetes Litigation
Court documents indicate that more than 1,600 Lipitor diabetes claims are currently pending in the U.S. District Court, District of South Carolina. All of the lawsuits accuse Pfizer Inc. of concealing the drug’s association with diabetes in order to protect its profits from Lipitor. Plaintiffs also assert that they would not have used Lipitor, or would have been more closely monitored for diabetes, had Pfizer’s warnings been adequate.
According to court records, the litigation involving Lipitor and diabetes has been growing since February 2012, when the U.S. Food & Drug Administration (FDA) announced that the labels for Lipitor and other statins would be updated to include new information about their potential association with Type 2 diabetes. While Pfizer did modify the Lipitor label in response to the FDA request, plaintiffs in Lipitor lawsuits claim that the new information is not sufficient to adequately warn patients about the drug’s association with diabetes.
Lipitor patients who allegedly developed Type 2 diabetes due to the medication may be entitled to compensation for medical bills, lost wages, pain and suffering, and other injury related damages. To learn more about filing a Lipitor lawsuit, please visit Bernstein Liebhard LLP’s website. To arrange for a free case review, please call 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have ben able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com